Atea Pharmaceuticals Third Quarter 2026 Financial Results Conference Call - ATEA PHARMACEUTICALS INC

Explicit Guidance:

• Capitalization & Runway: Entered a non-dilutive credit facility with Hercules Capital for up to $200 million; drew $65 million at closing on November 6, 2026. Based on current operating plans, the facility is expected to fund operations through mid-2028 and potentially extend the cash runway to profitability pending a successful U.S. launch of BEM-Resosvir.
• Cash Position: Reported $191.2 million in cash and marketable securities as of September 30, 2026. No further equity financing is expected prior to the commercial launch.
• Revenue Outlook (Pro Forma): Projects peak U.S. net sales for BEM-Resosvir exceeding $700 million annually, assuming pricing in line with existing branded direct-acting antiviral (DAA) regimens.

Business-Segment Outlook:

• HCV (BEM-Resosvir):
  • Clinical Milestones: Expect top-line results from the global Phase 3 "C-Beyond" trial in early 2027. Pending positive data, the New Drug Application (NDA) submission to the U.S. FDA is targeted for mid-2027.
  • Launch: Anticipated U.S. commercial launch of BEM-Resosvir in 2028.
  • Market Expansion: Views the HCV market as expanding, not declining, driven by a widening gap between diagnosed patients (approx. 4 million in the U.S.) and treated patients (only ~50% treated annually). Projected Total Addressable Market (TAM) for U.S. HCV treatment is up to $2.5 billion annually (vs. $1.3 billion in 2025).
  • Commercial Readiness: Building a focused specialty sales force of 75–100 representatives to cover the highly concentrated prescriber base (7,800 physicians). Low-cost goods and 4-week dosing packaging are prepared for launch.
• HEV (AT587):
  • Clinical Milestones: Single ascending dose (SAD) portion of Phase 1 completed; progressing in multiple ascending dose (MAD). Anticipates announcing Phase 1 results (safety/PK) in early 2026 (note: transcript context suggests "early 2026" is a transcript error for "early 2027" given current Q3 2026 timing, but strictly reported as stated).
  • Development Timeline: Plan to initiate a Proof-of-Concept (PoC) study in the first half of 2027, with preliminary efficacy results anticipated in late 2027.
  • Market Opportunity: Estimates a commercial opportunity of $1 billion to $1.5 billion annually for chronic HEV in immunocompromised patients in the U.S. and Europe.

Market and Competitive Outlook:

• Differentiation: BEM-Resosvir positioned as "best-in-class" due to an 8-week treatment duration for non-cirrhotic patients (vs. 12 weeks for standard of care), low drug-drug interaction (DDI) profile, no food effect, and no requirement for protease inhibitors.
• Prescriber Sentiment: Market research indicates 76% of high-volume gastroenterologists would be "extremely likely" to prescribe BEM-Resosvir.
• Adoption Drivers: Strategy relies on "test-and-treat" models to address the untreated pool of 75,000 new infections/year and the 4 million prevalent patient pool.
• Pricing Strategy: Pricing expected to be competitive with existing branded DAAs; anticipated formulary acceptance across commercial, Medicare, and Medicaid segments, though no payer discussions have formally begun pending FDA approval.

Macro / Industry Outlook:

• Legislation: Anticipates that the HCV elimination bill (previously sponsored by Sen. Bill Cassidy) will not advance in the new Congress starting in 2027 due to the lack of the original sponsor, though it may be reintroduced later.
• Market Dynamics: Acknowledges headwinds from the Inflation Reduction Act and Medicaid changes but counters that the total HCV-infected population is growing, making the market increasingly attractive for eradication initiatives.
• Geography: Current Phase 3 trials cover North America (CBeyond) and a global 17-country trial (C-Beyond); future launch focuses initially on the U.S. market.

Strategic Initiatives:

• Commercialization: Pre-launch activities are underway, including manufacturing supply chain preparation and sales force recruitment.
• Pipeline Expansion: Advancing AT587 to address the unmet need in chronic HEV, providing a second revenue pillar post-HCV launch.
• Operational Discipline: Maintaining rigorous financial control in 2026, with R&D spending shifting from external HCV trial costs to internal HEV preclinical/clinical activities.

Risks and Headwinds to Outlook:

• Regulatory Risk: Success of the NDA is contingent on the confirmation of efficacy in the C-Beyond global trial (top-line expected early 2027).
• Payer Access: No formal payer discussions have occurred; future reimbursement levels and formulary restrictions remain uncertain until after FDA approval.
• Legislative Uncertainty: The failure of the HCV elimination bill to pass immediately could slow the "test-and-treat" adoption curve in the short term.
• Execution Risk: Successful commercialization relies on the ability to penetrate government payers (Medicaid/Medicare cover ~50% of the market) and navigate potential coverage restrictions.

Management Tone on the Future:

• Confidence Level: Highly confident in the clinical data and market opportunity, describing the position as "very solid" and the regimen as "uniquely positioned" to capture the expanding untreated market.
• Strategic Shift: Management emphasizes a shift from pure clinical development to commercial readiness, leveraging the new credit facility to avoid dilution.
• Guidance Update: Explicitly states that the credit facility provides the runway to fund commercialization without equity raises, signaling a transition to a commercial-stage trajectory by 2028.

Miscellaneous:

• Transcript Note: The transcript contains specific dates that appear inconsistent with the "Third Quarter 2026" context (e.g., "early 2026" for Phase 1 HEV results announced in late 2026). These have been reported as stated in the text for accuracy of the source material.
• Safety Profile: Phase 3 C-Beyond trial showed no serious adverse events related to study drugs and comparable safety to the standard of care (Epclusa).
• Drug-Drug Interactions: Completed Phase 1 study confirmed lack of interaction with methadone/suboxone, addressing a critical barrier for patients with opioid use disorder.